RESEARCH MONOGRAPH · KDC-MN-180

Boswellia serrata

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

The acetyl-keto-boswellic acid (AKBA) fraction is genuinely interesting for inflammation, and most products dont contain enough of it

Boswellia serrata gum resin (frankincense from the Indian sub-continent) is one of the more legitimately interesting anti-inflammatory botanicals because the active fraction has a mechanism that's distinct from anything in the pharmaceutical anti-inflammatory toolbox. The pentacyclic triterpenoids called boswellic acids (alpha-boswellic acid, beta-boswellic acid, 11-keto-boswellic acid (KBA), and acetyl-11-keto-boswellic acid (AKBA)) are the relevant constituents, with AKBA being the most pharmacologically active.

The mechanism is 5-lipoxygenase inhibition. AKBA is a fairly selective non-redox 5-LOX inhibitor, which reduces leukotriene production via a pathway that NSAIDs and steroids dont directly hit. That gives boswellia a complementary anti-inflammatory profile to COX-inhibiting drugs, especially relevant in conditions where leukotriene biology drives pathology (asthma, ulcerative colitis, inflammatory joint disease).

Clinical evidence is reasonably good for osteoarthritis with several RCTs showing pain and function improvements at 100-250mg of high-AKBA extracts (5-Loxin and AprexFlex are the most-studied branded materials, both standardized to 30% AKBA). Effect sizes are competitive with low-dose NSAIDs in some trials. For ulcerative colitis there's some positive signal but less data. Asthma has historical Ayurvedic use plus some small modern trials but the modern asthma evidence is weaker than the joint data.

Sourcing is the crucial issue. AKBA content in commercial Boswellia extracts varies from 1-2% in cheap material up to 30-40% in standardized branded extracts. Standard total-boswellic-acid labeling (often 65% or 70%) doesnt tell you much because alpha- and beta-boswellic acids are not the active species, AKBA is. So you can have two products with identical total-BA labels and dramatically different actual activity.

The AKBA bioavailability story is also genuinely problematic. Free AKBA has very poor oral absorption, which is what motivated phytosome formulations (Casperome) and other delivery enhancements. Plain high-AKBA extract still works clinically, suggesting effective concentrations are reached at the gut or via small absorbed fractions, but pharmacokinetics here are limiting.

Safety profile is clean at supplemental doses with mild GI effects being the main practical issue.

What we like: legitimately distinct mechanism from NSAIDs, real OA evidence, and the AKBA story is one of the better-characterized natural-product anti-inflammatory stories around. What we dont like: most commercial Boswellia is grossly under-standardized for the actual active compound.

Evidence: 68
Mechanism: 80
Reliability: 70
Safety: 82
Sourcing: 55
Value: 65
Signal: 70
Staying power: 72

Plain-language summary Intrigue 55 / 100

Boswellia serrata is the source of frankincense gum resin. Boswellic acids inhibit 5-lipoxygenase and produce anti-inflammatory effects, particularly in osteoarthritis and inflammatory bowel disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Frankincense gum resin / boswellic acids

An Indian frankincense resin containing boswellic acids with selective 5-lipoxygenase inhibition for inflammatory conditions.

Abstract

Boswellia serrata (Indian frankincense) is a tree resin used in Ayurvedic medicine for inflammatory conditions, particularly osteoarthritis and inflammatory bowel disease. Active constituents are boswellic acids (acetyl-11-keto-beta-boswellic acid, AKBA, being the most pharmacologically characterized). Mechanism is selective inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene synthesis. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Boswellic acids; selective 5-lipoxygenase inhibition. Reduced leukotriene synthesis.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med 2006.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-180

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Boswellia serrata

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs